Trial Profile
First-line capecitabine + docetaxel versus epirubicin + docetaxel in women with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2011
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms CAPEDOC-EPIDOC; ERASME4
- Sponsors Roche; Sanofi
- 01 Jul 2011 Results published in Oncology.
- 05 Nov 2010 New trial record.